Financials in USD. Standardized financial statements.
A compact view of how Biora Therapeutics, Inc. turns revenue into operating income and net income.
| Metric | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|
| Revenue? | $4,000 | $305,000 | $1.25M | $74.31M | $143.99M | $127.97M |
| Revenue Growth? | -98.7% | -75.5% | -98.3% | -48.4% | +12.5% | 0.0% |
| Cost of Revenue? | $0 | $0 | $0 | $93.43M | $100.49M | $92.08M |
| Gross Profit? | $4,000 | $305,000 | $1.25M | -$19.12M | $43.49M | $35.90M |
| Gross Margin? | +100.0% | +100.0% | +100.0% | -25.7% | +30.2% | +28.1% |
| Operating Expenses? | $67.15M | $62.09M | $119.08M | $176.07M | $183.61M | $150.14M |
| Operating Income? | -$67.14M | -$61.78M | -$117.84M | -$107.62M | -$140.12M | -$114.24M |
| EBITDA? | -$114.05M | -$37.35M | -$164.57M | -$106.18M | -$135.44M | -$110.17M |
| Income Before Tax | -$124.42M | -$49.25M | -$178.64M | -$142.62M | -$148.74M | -$123.86M |
| Income Tax Expense | -$90,000 | -$420,000 | -$119,000 | -$37.53M | -$706,000 | $5.25M |
| Net Income? | -$124.11M | -$38.16M | -$178.52M | -$192.53M | -$148.04M | -$129.11M |
| EPS? | $-78.70 | $-6.40 | $-46.42 | $-86.30 | $-80.17 | $-119.71 |
| Diluted EPS? | $-78.70 | $-6.40 | $-46.42 | $-86.30 | $-80.17 | $-119.71 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality